p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer

• Published in: Diseases of the esophagus 1999-01, Vol.12 (2), p.116-119
• Main Authors: Kuwahara, M, Hirai, T, Yoshida, K, Yamashita, Y, Hihara, J, Inoue, H, Toge, T
• Format: Article
• Language: English
• Subjects: apoptosis; Cyclin D1 - analysis; Cyclin-Dependent Kinase Inhibitor p21; Cyclins - analysis; Enzyme Inhibitors - analysis; epithelium; Esophageal Neoplasms - metabolism; Esophageal Neoplasms - mortality; esophagus; Fas ligand; Fas receptor; Female; homeostasis; Humans; immunohistochemistry; in situ hybridization; Male; Prognosis; Proportional Hazards Models; Survival Rate; Tumor Suppressor Protein p53 - analysis
• ISSN: 1120-8694; 1442-2050
• DOI: 10.1046/j.1442-2050.1999.00034.x

Recently, various cell cycle regulators have been investigated as biological markers of malignant potential. These regulators might influence the survival rate and the effect of adjuvant therapies. In this study, we analyzed p53, p21(Waf1/Cip1) and cyclin D1 expression in 64 esophageal cancer patients and the relationship between clinicopathologic parameters and patient survival. The positive expression rate was 48.4%, 42.2% and 43.8% in the p53, p21 and cyclin D1 groups respectively. Multivariant analysis revealed that tumor depth, chemotherapy, p53, p21 and cyclin D1 expression showed significant values. p53‐ and cyclin D1‐negative patients had a worse prognosis. p21‐positive patients had a better prognosis. In stage 0, I and II patients, there was a significant difference between p53‐positive and ‐negative, p21‐positive and ‐negative, and cyclin D1‐positive and ‐negative groups. In stage III and IV patients, there was no significant difference between any two groups. However, a significant difference was seen in the p21 group: among patients who received adjuvant chemotherapy, the p21‐positive group had a 5‐year survival rate of 50% compared with 13.4% in the p21‐negative group (not significant).